Interestingly, [11C]Raclopride studies targeting dopamine D2 receptors, which co-localize with A2A receptors in striatum, have also shown a decrease in binding in caudate of early-stage PD patients while binding in the putamen was similar to healthy volunteers [29, 30]. The gene discussed is DRD2; the disease is Parkinson disease.